1190392-22-3

Usage

Uses

Used in Pharmaceutical Industry:
(6S)-4,6,7,8-tetrahydro-4-oxo-Pyrrolo[1,2-a]pyrimidine-6-carboxylic acid is used as a potential drug candidate for its various biological activities. It exhibits anti-tumor properties, making it a promising agent for the development of cancer treatments. (6S)-4,6,7,8-tetrahydro-4-oxo-Pyrrolo[1,2-a]pyriMidine-6-carboxylic acid's ability to target and inhibit specific enzymes and receptors involved in tumor growth and progression contributes to its potential as an anti-cancer agent.
Additionally, (6S)-4,6,7,8-tetrahydro-4-oxo-Pyrrolo[1,2-a]pyrimidine-6-carboxylic acid demonstrates anti-inflammatory effects, which can be utilized in the development of medications for inflammatory diseases. Its capacity to modulate immune responses and reduce inflammation can be beneficial in treating conditions such as arthritis, asthma, and other inflammatory disorders.
Furthermore, (6S)-4,6,7,8-tetrahydro-4-oxo-Pyrrolo[1,2-a]pyriMidine-6-carboxylic acid also possesses anti-fungal properties, which can be applied in the development of anti-fungal drugs. Its ability to inhibit fungal growth and prevent infections can be useful in treating various fungal diseases, including candidiasis, aspergillosis, and other mycoses.

Upstream product

• 1190392-23-4 methyl [6(S)-4-oxo-4,6,7,8-tetrahydropyrrolo[1,2-α]]pyrimidine-6-carboxylate 
• 1190709-67-1 methyl (7S)-9-oxo-3,8-diazatetracyclo[9.2.1.0(2,10).0(4,8)]tetradeca-3,12-diene-7-carboxylate 
• 173142-47-7 methyl (2S)-5-methoxy-3,4-dihydro-2H-pyrrole-2-carboxylate 

Downstream Products

• 1190393-25-9 tert-butyl(2R,5S)-2-[(R)-hydroxy(phenyl)methyl]-5-[4-({[(6S)-4-oxo-4,6,7,8-tetrahydropyrrolo[1,2-α]pyrimidin-6-yl]carbonyl}amino)benzyl]pyrrolidine-1-carboxylate 

Relevant academic research and scientific papers

NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS

The present invention provides compounds of Formula (I), pharmaceutical compositions thereof, and methods of using the same in the treatment or prevention of diseases mediated by the activation of β3-adrenoceptor. (I).

COMBINATION THERAPY USING A BETA 3 ADRENERGIC RECEPTOR AGONIST AND AN ANTIMUSCARINIC AGENT

Described herein is an improved method of treating overactive bladder, wherein the method comprises administering to a patient in need thereof a beta 3 adrenergic receptor agonist, an antimuscarinic agent, and an optional selective M2 antagonist. Such combination therapy provides improved efficacy and/or reduced side effects.

HYDROXYMETHYL PYRROLIDINES AS BETA 3 ADRENERGIC RECEPTOR AGONISTS

The present invention provides compounds of Formula I, pharmaceutical compositions thereof, and method of using the same in the treatment or prevention of diseases mediated by the activation of β3-adrenoceptor.

HYDROXYMETHYL PYRROLIDINES AS BETA 3 ADRENERGIC RECEPTOR AGONISTS

The present invention provides compounds of Formula (I), pharmaceutical compositions thereof, and method of using the same in the treatment or prevention of diseases mediated by the activation of β3-adrenoceptor.